Page last updated: 2024-09-05

tolvaptan and Ascites

tolvaptan has been researched along with Ascites in 49 studies

Research

Studies (49)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	30 (61.22)	24.3611
2020's	19 (38.78)	2.80

Authors

Authors	Studies
Roy, A; Singh, S	1
Eguchi, A; Iwasa, M; Shigefuku, R; Suzuki, T; Takei, Y; Tamai, Y; Tempaku, M	1
Honda, K; Inoue, D; Inoue, R; Nangaku, M; Nishi, H	1
Abe, M; Hiasa, Y; Hirooka, M; Koizumi, Y; Nakamura, Y; Sunago, K; Tokumoto, Y; Watanabe, T; Yano, R; Yoshida, O; Yukimoto, A	1
Arase, Y; Hara, T; Hirose, S; Kagawa, T; Koizumi, J; Mishima, Y; Ono, S; Sekiguchi, T; Sekiguchi, Y; Shiraishi, K; Tsuruya, K	1
Hosoda, S; Kitagataya, T; Kohya, R; Kubo, A; Morikawa, K; Nakai, M; Ogawa, K; Ohara, M; Sakamoto, N; Sasaki, T; Sho, T; Suda, G; Tokuchi, Y; Yamada, R; Yoshida, S	1
Hu, YY; Wang, YD; Zhang, X; Zhao, CY	1
Aikata, H; Chayama, K; Fujino, H; Hiramatsu, A; Imamura, M; Kawaoka, T; Kodama, K; Morio, K; Murakami, E; Nakahara, T; Namba, M; Ohya, K; Tsuge, M; Uchikawa, S; Yamauchi, M	1
Bellos, I; Kontzoglou, K; Pergialiotis, V; Psyrri, A	1
Chu, PS; Ebinuma, H; Ikura, A; Kanai, T; Morikawa, R; Nakamoto, N; Ojiro, K; Saito, H; Shiba, S; Taniki, N; Yamaguchi, A; Yamataka, K; Yoshida, A	1
Hiramine, Y; Hiwaki, T; Ido, A; Imamura, Y; Kanmura, S; Maenohara, S; Mawatari, S; Oku, M; Saishoji, A; Tokushige, K; Uto, H	1
Alukal, JJ; John, S; Thuluvath, PJ	1
Kojima, Y; Kudo, T; Murai, Y; Satoh, T; Uehara, K	1
Azumi, M; Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Kojima, Y; Nozawa, Y; Sano, T; Yoshida, T	1
Chen, C; Chen, Y; Cheng, J; Ding, H; Gao, Y; Han, T; Ji, F; Jia, J; Jiang, X; Lv, N; Mao, Q; Mao, Y; Niu, J; Shang, J; Tang, J; Wang, Y; Wang, Z; Wei, Z; Zeng, M; Zhang, Q	1
Eguchi, Y; Hirashima, N; Ikejima, K; Ishikawa, T; Kawai, Y; Kawaratani, H; Kogiso, T; Komori, A; Matsumoto, N; Motoyama, H; Nakajima, T; Nojima, M; Onishi, M; Saito, S; Sawai, H; Shimada, N; Tanaka, Y; Tateyama, M; Terai, S; Uojima, H; Yoshiji, H	1
Enomoto, N; Hayakawa, Y; Higuchi, M; Inada, K; Itakura, J; Izumi, N; Kaneko, S; Kirino, S; Komiyama, Y; Kurosaki, M; Maeyashiki, C; Nakanishi, H; Okada, M; Osawa, L; Sekiguchi, S; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Tsuchiya, K; Wang, W; Yamashita, K; Yasui, Y	1
Enomoto, N; Gotou, T; Hayashi, T; Higuchi, M; Itakura, J; Izumi, N; Komiyama, Y; Kubota, Y; Kurosaki, M; Nakanishi, H; Oh, W; Okada, M; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Yasui, Y	1
Goya, T; Kato, M; Kohjima, M; Kotoh, K; Masumoto, A; Miyazaki, M; Motomura, K; Senjyu, T; Tanaka, K; Yada, M	1
Hashimoto, E; Ikarashi, Y; Kobayashi, M; Kodama, K; Kogiso, T; Taniai, M; Tokushige, K; Torii, N; Yamamoto, K	1
Egashira, H; Hidaka, H; Ichita, C; Kako, M; Koizumi, K; Masuda, S; Nakayama, T; Sasaki, A; Sung, JH; Tokoro, S; Uojima, H	1
Chen, CW; Chen, YX; Cheng, J; Ding, HG; Han, T; Mao, Q; Mao, YM; Niu, JQ; Tang, JT; Wang, MR; Wang, YF; Wang, ZH; Wei, Z; Xie, Q; Yang, YP; Ye, WJ; Zeng, M	1
Abe, K; Fujita, M; Hayashi, M; Ohira, H; Okai, K; Takahashi, A	1
Abe, M; Hiasa, Y; Hirooka, M; Imai, Y; Koizumi, Y; Watanabe, T; Yoshida, O; Yukimoto, A	1
Atarashi, Y; Ito, H; Kawai, K; Minemura, M; Shimizu, Y; Sugiyama, T; Tajiri, K; Takahara, T; Tokimitsu, Y; Yasumura, S	1
Ding, HG; Han, T; Li, Y; Liebe, R; Ma, H; Wang, S; Weng, H; Xie, W; Zhang, X	1
Hidaka, I; Ishikawa, T; Iwamoto, T; Maeda, M; Saeki, I; Sakaida, I; Tajima, K; Takami, T	1
Kodama, K; Kogiso, T; Sagawa, T; Taniai, M; Tokushige, K	1
Kida, Y	1
Ando, H; Fukada, H; Kanazawa, R; Kokubu, S; Miyazaki, A; Nakadera, E; Okubo, H; Sagawa, E; Sorin, Y	1
Hidaka, H; Kako, M; Koizumi, W; Kubota, K; Nakazawa, T; Shibuya, A; Sung, JH; Tanaka, Y; Uojima, H; Wada, N	1
Ishihara, T; Isoai, A; Iwasa, M; Kato, M; Kobayashi, R; Soneda, N; Takei, Y; Torii, N	1
Bellos, I; Kontzoglou, K; Perrea, DN	1
Kobayashi, T; Komatsu, M; Komorizono, Y; Okada, M; Okita, K; Sakai, T; Sakaida, I; Yamashita, S	1
Sakaida, I	1
Ding, HG; Dong, PL; Fan, CL; Li, B; Li, L; Li, P; Wang, SZ; Zhang, X; Zhao, WM; Zheng, JF	1
Goto, A; Matsumoto, M; Nakamura, M; Sakaida, I; Terai, S	1
Akiyama, T; Aoki, Y; Hosokawa, I; Kato, A; Kawamoto, J; Kuboki, S; Mitsuhashi, N; Miyazaki, M; Nemoto, S; Nishino, H; Ohtsuka, M; Sasaki, K; Satoh, Y; Shimazaki, R; Shimizu, H; Shimizu, Y; Teranaka, R; Ueda, A; Yoichi, T; Yoshitomi, H	1
Hayashi, T; Higuchi, M; Hosokawa, T; Itakura, J; Izumi, N; Komiyama, Y; Kurosaki, M; Kuwabara, K; Nakakuki, N; Nakanishi, H; Sasaki, S; Suzuki, S; Takada, H; Takahashi, Y; Takaura, K; Tamaki, N; Yasui, Y; Yoshida, T	1
Chen, C; Chen, RP; Huang, XL; Huang, ZM; Lin, HH; Zhang, WY	1
Nakajima, K; Sakaida, I; Shibasaki, Y; Tachikawa, S; Terai, S; Tsubouchi, H	1
Hayata, Y; Ito, D; Karasawa, Y; Kawamura, S; Kojima, K; Ohki, T; Seki, M; Tagawa, K; Toda, N; Yamada, T	1
Bhalla, A; Rai, N; Sharma, N; Singh, A; Singh, B; Singh, V; Vijayvergiya, R	1
Izumi, N; Kurosaki, M	1
Izumi, N; Kurosaki, M; Nakanishi, H	1
Chayama, K; Kaneko, A; Kato, M; Murawaki, Y; Okada, M; Okita, K; Ono, N; Sakaida, I; Sata, M; Yoshihara, H; Yoshihara, N	1
Afdhal, NH; Cárdenas, A; Czerwiec, F; Ginès, P; Guevara, M; Marotta, P; Oyuang, J	1
Dahl, E; Gluud, LL; Kimer, N; Krag, A	1
Kobayashi, Y; Okada, M; Okita, K; Sakaida, I; Yanase, M; Yasutake, T	1

Reviews

6 review(s) available for tolvaptan and Ascites

Article	Year
Tolvaptan Response Improves Overall Survival in Patients with Refractory Ascites: A Meta-Analysis. Digestive diseases (Basel, Switzerland), 2020, Volume: 38, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Ascites; Female; Humans; Male; Middle Aged; Risk Factors; Survival Analysis; Tolvaptan; Treatment Outcome	2020
Hyponatremia in Cirrhosis: An Update. The American journal of gastroenterology, 2020, Volume: 115, Issue:11 Topics: Acute Kidney Injury; Acute-On-Chronic Liver Failure; Albumins; Antidiuretic Hormone Receptor Antagonists; Ascites; Fluid Therapy; Hepatic Encephalopathy; Hepatorenal Syndrome; Humans; Hypertension, Portal; Hyponatremia; Liver Cirrhosis; Liver Transplantation; Renin-Angiotensin System; Saline Solution, Hypertonic; Splanchnic Circulation; Tolvaptan; Vasodilation; Vasopressins	2020
Predictors of tolvaptan short-term response in patients with refractory ascites: A meta-analysis. Journal of gastroenterology and hepatology, 2020, Volume: 35, Issue:2 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Blood Urea Nitrogen; Body Weight; C-Reactive Protein; Forecasting; Hepatitis C; Humans; Time Factors; Tolvaptan	2020
Tolvaptan for the treatment of liver cirrhosis oedema. Expert review of gastroenterology & hepatology, 2014, Volume: 8, Issue:5 Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Edema; Humans; Liver Cirrhosis; Tolvaptan; Treatment Outcome	2014
Management of ascites in cirrhotic patients. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2017, Volume: 114, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Diuretics; Humans; Japan; Liver Cirrhosis; Practice Guidelines as Topic; Receptors, Vasopressin; Signal Transduction; Sodium Potassium Chloride Symporter Inhibitors; Spironolactone; Tolvaptan; Vasopressins	2017
Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Alimentary pharmacology & therapeutics, 2012, Volume: 36, Issue:7 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzamides; Benzazepines; Humans; Hyponatremia; Liver Cirrhosis; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Sodium; Spiro Compounds; Tolvaptan; Treatment Outcome	2012

Trials

12 trial(s) available for tolvaptan and Ascites

Article	Year
Efficacy and safety of tolvaptan in patients with malignant ascites: a phase 2, multicenter, open-label, dose-escalation study. Japanese journal of clinical oncology, 2021, Mar-03, Volume: 51, Issue:3 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Female; Humans; Male; Tolvaptan; Treatment Outcome	2021
Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC gastroenterology, 2020, Nov-19, Volume: 20, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; China; Diuretics; Humans; Liver Cirrhosis; Tolvaptan	2020
Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study. World journal of gastroenterology, 2017, Dec-07, Volume: 23, Issue:45 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Drug Therapy, Combination; Female; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tolvaptan; Treatment Outcome	2017
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial. Journal of digestive diseases, 2018, Volume: 19, Issue:3 Topics: Abdomen; Adolescent; Adult; Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Sodium; Tolvaptan; Urine; Young Adult	2018
Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia. BMC gastroenterology, 2018, Sep-04, Volume: 18, Issue:1 Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Double-Blind Method; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Sodium; Survival Rate; Tolvaptan	2018
Furosemide Dose Changes Associated with Furosemide/Tolvaptan Combination Therapy in Patients with Cirrhosis. Digestive diseases (Basel, Switzerland), 2020, Volume: 38, Issue:1 Topics: Aged; Aged, 80 and over; Ascites; Body Weight; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Furosemide; Glomerular Filtration Rate; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Tolvaptan	2020
Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. The Journal of international medical research, 2013, Volume: 41, Issue:3 Topics: Aged; Ascites; Benzazepines; Body Weight; Diuretics; Drug Administration Schedule; Edema; Female; Humans; Liver; Liver Cirrhosis; Male; Middle Aged; Protective Agents; Sodium; Tolvaptan; Treatment Outcome	2013
Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Journal of gastroenterology, 2017, Volume: 52, Issue:2 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Blood Urea Nitrogen; Body Weight; Female; Humans; Japan; Liver Cirrhosis; Male; Middle Aged; Predictive Value of Tests; Tolvaptan; Urine	2017
Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites: a randomised pilot study. Liver international : official journal of the International Association for the Study of the Liver, 2017, Volume: 37, Issue:3 Topics: Adult; Ascites; Benzazepines; Drug Therapy, Combination; Female; Humans; India; Liver Cirrhosis; Male; Middle Aged; Midodrine; Pilot Projects; Sodium; Tertiary Care Centers; Time Factors; Tolvaptan; Vasoconstrictor Agents	2017
A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. Journal of gastroenterology, 2010, Volume: 45, Issue:9 Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Dose-Response Relationship, Drug; Edema; Female; Furosemide; Humans; Japan; Liver Cirrhosis; Lower Extremity; Male; Middle Aged; Tolvaptan; Treatment Outcome; Waist Circumference	2010
Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. Journal of hepatology, 2012, Volume: 56, Issue:3 Topics: Administration, Oral; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Chronic Disease; Female; Health Surveys; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Recurrence; Sodium; Tolvaptan; Treatment Outcome	2012
The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. The Journal of international medical research, 2012, Volume: 40, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Double-Blind Method; Electrolytes; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Tolvaptan	2012

Other Studies

31 other study(ies) available for tolvaptan and Ascites

Article	Year
Tolvaptan for difficult- to -treat ascites: Difficulties in opening doors for GWAS application. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:12 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Genome-Wide Association Study; Humans; Sodium; Tolvaptan	2021
Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites. Internal medicine (Tokyo, Japan), 2021, Volume: 60, Issue:21 Topics: Adipokines; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Biomarkers; Glycopeptides; Glycoproteins; Humans; Liver Cirrhosis; Tolvaptan; Zinc	2021
Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2020, 08-27, Volume: 1, Issue:8 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Humans; Hyponatremia; Polycystic Kidney, Autosomal Dominant; Tolvaptan	2020
Cisterna chyli as an optimal marker of tolvaptan response in severe cirrhotic ascites. Scientific reports, 2022, 05-17, Volume: 12, Issue:1 Topics: Ascites; Humans; Liver Cirrhosis; Retrospective Studies; Thoracic Duct; Tolvaptan	2022
First reports of clinical effects of transjugular intrahepatic portosystemic shunt in four patients with cirrhotic ascites refractory to tolvaptan. BMJ open gastroenterology, 2023, Volume: 10, Issue:1 Topics: Ascites; End Stage Liver Disease; Humans; Liver Cirrhosis; Portasystemic Shunt, Transjugular Intrahepatic; Quality of Life; Retrospective Studies; Severity of Illness Index; Tolvaptan	2023
Neutrophil gelatinase-associated lipocalin predicts the efficacy of tolvaptan for ascites in patients with liver cirrhosis. Journal of gastroenterology, 2023, Volume: 58, Issue:7 Topics: Acute Kidney Injury; Acute-Phase Proteins; Ascites; Biomarkers; C-Reactive Protein; Humans; Lipocalin-2; Lipocalins; Liver Cirrhosis; Proto-Oncogene Proteins; Tolvaptan; Water	2023
[Research progress of arginine vasopressin V2 receptor antagonist tolvaptan in the treatment of cirrhotic ascites]. Zhonghua nei ke za zhi, 2023, Jul-01, Volume: 62, Issue:7 Topics: Ascites; Humans; Liver Cirrhosis; Receptors, Vasopressin; Sodium; Tolvaptan	2023
Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis. Journal of gastroenterology, 2020, Volume: 55, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Female; Follow-Up Studies; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Muscle, Skeletal; Organ Size; Prognosis; Retreatment; Retrospective Studies; Sarcopenia; Survival Rate; Time Factors; Tolvaptan; Tomography, X-Ray Computed; Young Adult	2020
Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study. BMC gastroenterology, 2020, Mar-05, Volume: 20, Issue:1 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Fluids; Electric Impedance; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Monitoring, Physiologic; Tolvaptan	2020
Impact of acute kidney injury on prognosis and the effect of tolvaptan in patients with hepatic ascites. Journal of gastroenterology, 2021, Volume: 56, Issue:1 Topics: Acute Kidney Injury; Administration, Oral; Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Drug Therapy, Combination; Female; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Prognosis; Propensity Score; Retrospective Studies; Survival Analysis; Tolvaptan; Treatment Outcome	2021
Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma. European journal of gastroenterology & hepatology, 2021, 12-01, Volume: 33, Issue:1S Suppl 1 Topics: Aged; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Prognosis; Retrospective Studies; Tolvaptan; Treatment Outcome	2021
A genome-wide association study identifying SVEP1 variant as a predictor of response to tolvaptan for cirrhotic ascites. Liver international : official journal of the International Association for the Study of the Liver, 2021, Volume: 41, Issue:12 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Cell Adhesion Molecules; Genome-Wide Association Study; Humans; Liver Cirrhosis; Tolvaptan	2021
Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan. Digestive diseases (Basel, Switzerland), 2022, Volume: 40, Issue:4 Topics: Ascites; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Prognosis; Renin; Retrospective Studies; Tolvaptan	2022
Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. PloS one, 2017, Volume: 12, Issue:3 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Diuretics; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Potassium; Sodium; Tolvaptan; Treatment Outcome; Weight Loss	2017
Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma. World journal of gastroenterology, 2017, Aug-07, Volume: 23, Issue:29 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Body Weight; Carcinoma, Hepatocellular; Disease Progression; Diuretics; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Furosemide; Humans; Liver; Liver Failure; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Spironolactone; Tolvaptan; Treatment Outcome	2017
The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan. Internal medicine (Tokyo, Japan), 2017, Nov-15, Volume: 56, Issue:22 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Hyponatremia; Japan; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome	2017
Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia. Internal medicine (Tokyo, Japan), 2018, Sep-01, Volume: 57, Issue:17 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Prognosis; Retrospective Studies; Sodium; Tolvaptan; Treatment Outcome	2018
Validation trial for efficacy of ultrasonographic measurement method to predict ascitic volume using virtual ultrasonography. Journal of medical ultrasonics (2001), 2018, Volume: 45, Issue:4 Topics: Abdomen; Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Humans; Imaging, Three-Dimensional; Liver Cirrhosis; Male; Middle Aged; Pelvis; Retrospective Studies; Tolvaptan; Tomography, X-Ray Computed; Ultrasonography	2018
Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis. Digestive diseases (Basel, Switzerland), 2018, Volume: 36, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; ROC Curve; Survival Analysis; Tolvaptan; Treatment Outcome	2018
Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites. Journal of gastroenterology and hepatology, 2019, Volume: 34, Issue:7 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Diuretics; Drug Interactions; Drug Resistance; Female; Humans; Kidney; Liver Cirrhosis; Male; Middle Aged; Remission Induction; Retrospective Studies; Time Factors; Tolvaptan; Treatment Outcome	2019
Impact of continued administration of tolvaptan on cirrhotic patients with ascites. BMC pharmacology & toxicology, 2018, Dec-18, Volume: 19, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Ammonia; Antidiuretic Hormone Receptor Antagonists; Ascites; Body Weight; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Serum Albumin; Tolvaptan; Treatment Outcome; Young Adult	2018
Positive Response to Tolvaptan Treatment Would Be a Good Prognostic Factor for Cirrhotic Patients with Ascites. Digestive diseases (Basel, Switzerland), 2019, Volume: 37, Issue:3 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Ascites; Female; Furosemide; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Tolvaptan; Treatment Outcome	2019
Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites. Journal of pharmacological sciences, 2019, Volume: 139, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Edema; Female; Humans; Liver Cirrhosis; Liver Diseases; Male; Middle Aged; Serum Albumin; Tolvaptan; Treatment Outcome	2019
Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan. Internal medicine (Tokyo, Japan), 2019, Nov-01, Volume: 58, Issue:21 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Ascitic Fluid; Diuretics; Female; Fluid Therapy; Furosemide; Humans; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Serum Albumin; Spironolactone; Tolvaptan	2019
Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World journal of gastroenterology, 2014, Aug-28, Volume: 20, Issue:32 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Biomarkers; Edema; Female; Humans; Hyponatremia; Liver Cirrhosis; Male; Middle Aged; Sodium; Time Factors; Tolvaptan; Treatment Outcome; Urination; Urodynamics	2014
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites. Clinical journal of gastroenterology, 2015, Volume: 8, Issue:1 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Furosemide; Humans; Liver Cirrhosis; Male; Spironolactone; Tolvaptan	2015
[Effect of tolvaptan on ascites due to malignancy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:2 Topics: Aged; Aged, 80 and over; Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Female; Humans; Male; Middle Aged; Neoplasms; Tolvaptan	2015
Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. Journal of gastroenterology, 2016, Volume: 51, Issue:6 Topics: Aged; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Ascites; Benzazepines; Female; Humans; Liver Cirrhosis; Male; Middle Aged; Retrospective Studies; Tolvaptan	2016
Tolvaptan regulates aquaporin-2 and fecal water in cirrhotic rats with ascites. World journal of gastroenterology, 2016, Mar-28, Volume: 22, Issue:12 Topics: Animals; Aquaporin 2; Ascites; Benzazepines; Carbon Tetrachloride; Colon; Diarrhea; Dose-Response Relationship, Drug; Feces; Liver Cirrhosis, Experimental; Male; Rats, Sprague-Dawley; Sodium; Time Factors; Tolvaptan; Vasopressins; Water	2016
Potential Effectiveness of Tolvaptan to Improve Ascites Unresponsive to Standard Diuretics and Overall Survival in Patients with Decompensated Liver Cirrhosis. Clinical drug investigation, 2016, Volume: 36, Issue:10 Topics: Aged; Ascites; Benzazepines; Carcinoma, Hepatocellular; Diuretics; Female; Humans; Hyponatremia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Tolvaptan	2016
Tolvaptan for the Treatment of Refractory Ascites. Internal medicine (Tokyo, Japan), 2016, Volume: 55, Issue:20 Topics: Antidiuretic Hormone Receptor Antagonists; Ascites; Benzazepines; Humans; Liver Cirrhosis; Tolvaptan	2016